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Received October 22, 2015; accepted February 21, 2016AbstractBackground: There was no consensus about the management of patients with urinary retention and elevated serum prostate-specific antigen
(PSA) levels. This study aimed to determine whether concomitant transrectal ultrasound (TRUS)-guided biopsy and transurethral resection of
prostate (TURP) is practical in patients with urinary retention and elevated serum PSA levels.
Methods: From March 2007 to May 2015, a total of 34 patients with urinary retention and elevated PSA ( 4 ng/mL) underwent concomitant
TRUS-guided biopsy and TURP. The medical records were evaluated retrospectively, and data including PSA, prostate volume, TURP results,
TRUS-guided biopsy results, length of hospitalization, and complications were collected. These patients were then compared with 40 patients
with urinary retention who underwent TURP alone.
Results: The mean age of the patients was 71.6 years. The mean PSA levels were 16.9 ng/mL. Prostate cancer was detected in eight cases
(23.5%): one case by TRUS-guided biopsy alone, two cases by TURP alone, and five cases by both TRUS-guided biopsy and TURP. Com-
plications included fever in five patients (14.7%), recatheterization for urine retention in two patients (5.9%), urinary tract infection in two
patients (5.9%), and de novo urge incontinence in seven patients (20.6%). The complication rate was not significantly increased compared with
that of the patients who underwent TURP alone.
Conclusion: This study showed that concomitant TRUS-guided biopsy and TURP was safe and of possible clinical significance in urinary
retention patients with elevated serum PSA.
Copyright © 2016, the Chinese Medical Association. Published by Elsevier Taiwan LLC. This is an open access article under the CC BY-NC-
ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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An increase in serum prostate-specific antigen (PSA) levels
in patients with urinary retention has been frequently
reported.1e3 In clinical settings, it is sometimes difficult to
determine the cause of PSA elevation. Routine PSA testing
before transurethral resection of prostate (TURP) in these
patients remains controversial. Some urologists advocate
preoperative PSA testing, while others find it unnecessary andsevier Taiwan LLC. This is an open access article under the CC BY-NC-ND
Table 1
Comparison of patients with prostate cancer and BPH.
All patients Prostate cancer BPH p
No. of patients n ¼ 34 n ¼ 8 n ¼ 26
Age (y) 71.6 ± 7.0 74.4 ± 7.3 70.8 ± 6.8 0.209
PSA (ng/mL) 10.9 (5.7e67.1) 12 (7.5e58.4) 10.5 (5.6e55.9) 0.653
Prostate volume
(cm3)
60.8 ± 32.0 42.3 ± 23.5 66.4 ± 32.6 0.068
PSAD 0.36 ± 0.43 0.66 ± 0.73 0.27 ± 0.23 0.177
BPH ¼ benign prostatic hyperplasia; PSA ¼ prostate-specific antigen;
PSAD ¼ prostate-specific antigen density.
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transrectal ultrasound (TRUS)-guided biopsy carries certain
risks, because the biopsy may worsen the urinary retention and
may result in complications. Factors influencing the decision
of whether or not to perform the biopsy include the patient's
age, willingness, health condition, past PSA data, past biopsy
results, and the urologist's preferences. The aim of this study
was to determine whether concomitant TRUS-guided biopsy
and TURP was viable in patients with urinary retention and
elevated serum PSA ( 4 ng/mL).
2. Methods
We retrospectively reviewed patients referred to the urology
department for urinary retention fromMarch 2007 toMay 2015.
Patients older than 80 years and those with serum PSA < 4 ng/
mL or PSA  100 ng/mL were excluded from this study. These
patients were excluded because the value of prostatic biopsy in
this age group was questionable, and serum PSA  100 ng/mL
was regarded as an important indicator of metastatic disease.
Patients with trauma- or drug-related bladder outlet obstruction,
previous bladder or prostate malignancies, acute neurologic
conditions, and urosepsis were also excluded. All patients
signed an informed consent document before the operation. A
total of 34 patients underwent concomitant TRUS-guided
prostate biopsy and TURP. Prostate volume was measured by
transrectal ultrasound (BK Medical Hawk 2102 EXL; BK
Medical, Herlev, Denmark). All patients received bowel prep-
aration with cleansing phosphate enema (Evac enema, 118 mL)
the night before surgery and perioperatively were intravenously
administered a prophylactic broad-spectrum antibiotic. Under
spinal or general anesthesia, the patient was placed in the li-
thotomy position. A 12-core needle biopsy using an 18-gauge
needle biopsy gun (Bard Peripheral Vascular Inc., Tempe, AZ,
USA) was performed under transrectal ultrasound guidance.
Routine fiberocystoscopy was performed to rule out any un-
expected prostatic and bladder lesions. Bipolar TURP (Plas-
maKinetic Tissue Management System; Gyrus Medical Ltd.,
Cardiff, UK) was carried out using the standard procedures.
Oral quinolone was given for 5 days. The pathologist examined
the resected prostate chips and biopsy specimens separately.
The patients' demographic data, preoperative PSA levels,
prostate volume, PSA density, length of hospitalization, length
of catheterization, recatheterization rate, postoperative com-
plications, and TURP and biopsy pathological results were
recorded. Results were compared to those of a separate cohort
of 40 patients with prostate enlargement-related urinary
retention who underwent TURP alone during the study period.
In these 40 patients, PSA testing was not collected before
TURP. The results were compared using an independent t test
and Fisher's exact test. A p value < 0.05 was considered to be
statistically significant.
3. Results
The mean age of the patients was 71.6 years. The mean PSA
levels were 16.9 ng/mL. The mean prostate volume was60.8 cm3. Comparison between patients with cancer and benign
prostatic hyperplasia (BPH) showed no statistically significant
differences in patients' age, serum PSA levels, prostate volume,
and prostate-specific antigen density (PSAD; Table 1).
Overall, prostate cancer was detected in eight cases (23.5%;
Table 2); itwas detected by bothTRUS-guided biopsy andTURP
in five cases, by TURP alone in two cases, and by biopsy alone in
one case. In the case diagnosed by biopsy alone, the PSA levels
were 6.66 ng/mL, adenocarcinomawas found in all 12 cores, and
the Gleason score was 5 þ 5. The Gleason score was 3 þ 3 and
3 þ 4 in the two cases detected by TURP alone.
No statistically significant differences in patient age, post-
operative fever, recatheterization for urine retention, urge in-
continence, urinary tract infection, bladder neck contracture,
length of hospitalization, and length of catheterization were
found. The cancer detection rate was significantly higher (8/34
vs. 2/40; p ¼ 0.023) in the group of concomitant TRUS-guided
biopsy and TURP (Table 3).
4. Discussion
Urinary retention is the main indication for surgery in
approximately one fourth of male patients who undergo
TURP.5 It has been reported that urinary retention increases
the serum PSA levels by up to six-fold over the normal lim-
its.1e3 There is no consensus regarding the standard approach
to this condition. Some doctors advocate TURP alone, while
others routinely perform preoperative TRUS-guided biopsy.
Chen et al6 reported simultaneous TURP and TRUS-guided
biopsy to release acute urinary retention and documented a
definite diagnosis. We excluded patients older than 80 years
because the value of prostatic biopsy in this age group was
questionable, and serum PSA  100 ng/mL was excluded
because it was regarded as an important indicator of metastatic
disease.7,8
The rate of incidental cancer detected by TURP was 22%
before PSA testing, and decreased to 9.8% in the past two
decades.9 In our study, prostate cancer was found in eight of
34 patients (23.5%). Most of the cancers (7/8) were found in
the TURP chips. However, the one case missed in the TURP
chips and detected by concomitant TRUS-guided biopsy was a
high-risk cancer (Gleason 5 þ 5) with PSA of 6.66 ng/mL.
This result stresses the importance of preoperative explanation
to the patient. There were no Gleason scores higher than 8 in
the TURP chips. This observation also concurs with earlier
Table 2
Characteristics of patients with prostate cancer.
Patient
No.
Age
(y)
Prostate
volume
(cm3)
PSA
(ng/mL)
PSAD
(ng/mL/cm3)
Pathological results
(Gleason score)
TRUS-guided
biopsy
TURP
1 71 88.0 7.13 0.08 Negative 3 þ 3
2 59 17.8 12.00 0.67 4 þ 3 4 þ 3
3 79 58.8 6.66 0.11 5 þ 5 Negative
4 78 28.9 63.42 2.19 3 þ 4 4 þ 3
5 79 45.9 9.69 0.21 4 þ 3 3 þ 3
6 79 53.0 11.98 0.23 Negative 3 þ 4
7 70 23.6 30.22 1.28 5 þ 3 3 þ 5
8 80 26.6 14.24 0.54 4 þ 3 3 þ 4
PSA ¼ prostate-specific antigen; PSAD ¼ prostate-specific antigen density;
TRUS ¼ transrectal ultrasound; TURP ¼ transurethral resection of prostate.
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transitional zone are usually less invasive than those origi-
nating in the peripheral zone.10 In the cohort of 40 patients
who underwent TURP alone without testing PSA levels before
the operation, the cancer detection rate was 5%. The signifi-
cantly higher ( p ¼ 0.023) cancer detection rate can be
explained by the following factors: patients in the group of
concomitant TRUS-guided biopsy and TURP had elevated
PSA levels, however, the PSA level was not checked in the
other 40 patients, resulting in an unknown ratio of elevated- to
normal-PSA levels. The higher cancer detection rate can also
be attributed to TRUS-guided biopsy, which was obtained
from the peripheral zone tissue.
The patients we enrolled into the study underwent prostate
ultrasound after Foley catheterization for acute urinaryTable 3
Comparisons of complications and cancer detection rate between TURP alone and
All patients
n ¼ 74
TURP
n ¼ 40
Age (y) 71.1 ± 6.7 70.7 ± 6.4
Underlying disease
Hypertension 26 16
Diabetes mellitus 13 8
Coronary artery disease 5 1
Hyperlipidemia 3 2
Chronic kidney disease 1 0
Cerebrovascular accident 8 2
Congestive heart failure 2 1
Pulmonary tuberculosis 1 0
COPD 2 1
Asthma 2 1
Liver cirrhosis 1 1
Urolithiasis 8 3
Urge incontinence 15 (20.3) 8 (20)
Urinary retention 10 (13.5) 8 (20)
Fever 7 (9.5) 2 (5.0)
Urinary tract infection 2 (2.7) 0 (0)
Bladder neck contracture 2 (2.7) 1 (2.5)
Length of catheterization (d) 3 (2.0e16.8) 3 (2.0e25.9)
Length of hospitalization (d) 3.9 ± 1.5 4.0 ± 1.2
Cancer 10 (13.5) 2 (5.0)
Data are presented as n, n (%), n (range), or mean ± standard deviation.
* A p value < 0.05 is statistically significant.
COPD ¼ chronic obstructive pulmonary disease; TURP ¼ transurethral resection oretention. The measurement of prostate volume was influ-
enced by the catheter and inflammation. In addition, urinary
retention increases the serum PSA level with a wide range
from two- to six-fold.1,2 Comparison between patients with
cancer and BPH showed no statistically significant differ-
ences in PSAD. Hence, we consider that PSAD is not a
reliable cancer predictor for patients with acute urinary
retention.
Present-day complications of TURP are relatively minor
owing to improved technologies such as surgical devices and
imaging systems. Concomitant TRUS-guided biopsy and
TURP is safe, as shown in our study. The incidence of urinary
tract infection (UTI) after TRUS-guided biopsy ranges be-
tween 2% and 6%, and bacteremia was reported in ~30e50%
of these patients.11 Nam et al12 reported that the rate of
readmission within 30 days was 4.1% in patients who under-
went TRUS-guided biopsy, with infection as the main cause.
UTI occurred in 1.7e14.0% of patients after TURP.13 Due to
urinary retention and urethral catheterization, we used an
extended course of oral antibiotics to prevent postoperative
UTI. In our study, postoperative fever occurred in five patients
(14.3%), whereas two patients (5.7%) were readmitted due to
UTI confirmed by urine culture and bacteremia confirmed by
blood culture. In contemporary studies, the rate of urinary
retention post-TURP has been reported to be from 3% to 9.9%
and the rate of temporary urge incontinence was 30e40%.13,14
By comparison, 5.9% of our patients suffered from transient
urinary retention, while 20.6% patients complained of tem-
porary urge incontinence. Two recatheterized patients voided
successfully, and the incidence of de novo urge incontinence
declined to 2.9% after 6 months. Major late complications ofconcomitant TRUS-guided biopsy and TURP.
Concomitant TRUS-guided biopsy and TURP
n ¼ 34
p
71.6 ± 7.0 0.548
10 0.241
5 0.388
4 0.132
1 0.561
1 0.460
6 0.085
1 0.711
1 0.460
1 0.711
1 0.711
0 0.541
5 0.268
7 (20.6) 0.588
2 (5.9) 0.074
5 (14.7) 0.153
2 (5.9) 0.208
1 (2.9) 0.711
3 (1.8e10.5) 0.130
3.9 ± 1.8 0.911
8 (23.5) 0.023*
f prostate; TRUS ¼ transrectal ultrasound.
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bladder neck contracture (range, 0.3e9.2%).13 Only one pa-
tient in our study had bladder neck contracture at 14 months
and remained symptom-free after undergoing bladder neck
incision. Comparison with a cohort of patients who underwent
TURP alone, revealed no statistically significant differences in
patient age, postoperative fever, UTI, bladder neck contrac-
ture, recatheterization rate, urge incontinence, length of hos-
pitalization, and length of catheterization (Table 3). This result
attests to the safety of concomitant TRUS-guided biopsy and
TURP in urinary retention patients.
A potential disadvantage of concomitant TURP and TRUS-
guided biopsy concerns patients with prostate cancer who are
suitable candidates for radical prostatectomy. Previous studies
showed that patients with a history of TURP had poorer out-
comes after laparoscopic radical prostatectomy, and previous
TURP also presented a challenge to surgeons during robot-
assisted radical prostatectomy.15,16 However, other studies
reported that although the procedure is technically more
demanding, when performed by expert surgeons, the overall
urinary function outcomes and frequency of positive surgical
margins appear to be similar.17e21
Urodynamic studies were not performed in our patients
prior to surgery. Previous studies showed that even if preop-
erative urodynamic exams in urinary retention patients sug-
gested an unfavorable outcome, especially in those younger
than 80 years, most could void by themselves without cathe-
terization at 3 months post-TURP.22,23 Two of our patients
with temporary urinary retention requiring recatheterization
voided successfully 1 month post-TURP.
Limitations of our study include small sample size, varying
source of patients' referrals, and the retrospective nature of the
study. There were potential study biases in that many patients
were referred from other clinics and the interval between PSA
examination and acute urinary retention episode varies.
Further prospective multi-center studies with a larger sample
size are required to provide future guidelines for this contro-
versial clinical issue.
In conclusion, this study revealed the safety and value of
concomitant TRUS-guided biopsy and TURP in urinary
retention patients with elevated serum PSA. Concomitant
TRUS-guided biopsy is a viable option during TURP for pa-
tients with urinary retention and elevated serum PSA.
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